Onbrez Breezhaler
Onbrez Breezhaler contains indacaterol, a long-acting beta2-adrenergic agonist (LABA). It is designed to relax the muscles around the airways in the lungs, helping to keep them open and make breathing easier for adults suffering from Chronic Obstructive Pulmonary Disease (COPD). It is administered using a specialized dry powder inhaler device called the Breezhaler.
Dosage by Body Weight
The standard dose is the inhalation of the contents of one 150 mcg capsule once daily, administered at the same time each day using the Breezhaler inhaler. In severe cases, a doctor may prescribe a 300 mcg dose once daily. The capsules must not be swallowed; they are for inhalation use only.
- Body Weight
- Below 5 kg
- Dose
- Not indicated
- Frequency
- Do not use
- Tracking Notes
- COPD does not occur in this population. Safety and efficacy in pediatric patients have not been established.
- Body Weight
- 5-7 kg
- Dose
- Not indicated
- Frequency
- Do not use
- Tracking Notes
- COPD does not occur in this population. Safety and efficacy in pediatric patients have not been established.
- Body Weight
- 8-10 kg
- Dose
- Not indicated
- Frequency
- Do not use
- Tracking Notes
- COPD does not occur in this population. Safety and efficacy in pediatric patients have not been established.
- Body Weight
- 11-15 kg
- Dose
- Not indicated
- Frequency
- Do not use
- Tracking Notes
- COPD does not occur in this population. Safety and efficacy in pediatric patients have not been established.
- Body Weight
- 16-20 kg
- Dose
- Not indicated
- Frequency
- Do not use
- Tracking Notes
- COPD does not occur in this population. Safety and efficacy in pediatric patients have not been established.
| Body Weight | Dose | Frequency | Tracking Notes |
|---|---|---|---|
| Below 5 kg | Not indicated | Do not use | COPD does not occur in this population. Safety and efficacy in pediatric patients have not been established. |
| 5-7 kg | Not indicated | Do not use | COPD does not occur in this population. Safety and efficacy in pediatric patients have not been established. |
| 8-10 kg | Not indicated | Do not use | COPD does not occur in this population. Safety and efficacy in pediatric patients have not been established. |
| 11-15 kg | Not indicated | Do not use | COPD does not occur in this population. Safety and efficacy in pediatric patients have not been established. |
| 16-20 kg | Not indicated | Do not use | COPD does not occur in this population. Safety and efficacy in pediatric patients have not been established. |
Formulation
Purpose
Maintenance bronchodilator treatment of airflow obstruction in adult patients with chronic obstructive pulmonary disease (COPD).
Generic Name
IndacaterolScheduled Drug
Yes. This medicine should be supplied or used only according to applicable prescription and regulatory requirements.